Qiagen NV


  • Ever since James Watson and Francis Crick discovered the structure of DNA in 1953, scientists have been puzzling over how genes make us who we are.

  • --Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.

  • --Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.

  • RESEARCH ALERT-HSBC cuts Stratec Biomedical to neutral Thursday, 11 Oct 2012 | 2:07 AM ET

    *HSBC cuts Stratec Biomedical to neutral from overweight. *HSBC cuts Carl Zeiss Meditec to underweight from neutral. *HSBC cuts Qiagen to underweight from neutral.

  • Stocks to Watch: KFT, LNKD, AIG & More Thursday, 3 May 2012 | 4:31 PM ET

    Check out which companies are making headlines after-the-bell Thursday:

  • Earnings Roundup: Nov. 8 Monday, 8 Nov 2010 | 4:16 PM ET

    What follows is a roundup of corporate earnings reports for Monday, Nov. 8.

  • Earnings Roundup: Aug. 9 Monday, 9 Aug 2010 | 8:31 AM ET

    What follows is a roundup of corporate earnings reports for Monday, Aug. 9.

  • A Beaker Full Of Biotech Stocks Wednesday, 21 Jan 2009 | 12:00 PM ET

    Sarat Sethi of Douglas C. Lane & Associates thinks investors ought to buy stocks, but must choose very carefully before they do. "I think it's too early to get into areas where companies are too levered, because capital markets are still not fully open," he told CNBC. "I would stick with the consumer staples, companies that have good international diversification, and health care, especially life sciences and medical products."

  • Dutch Biotech Qiagen to Buy Digene for $1.5 Billion Monday, 4 Jun 2007 | 8:25 AM ET

    Dutch biotechnology firm Qiagen said it will acquire Digene in a transaction valued at around $1.5 billion, to create a leader in molecular diagnostics.